吉非替尼治疗16例晚期非小细胞肺癌的临床疗效

Gefitinib in the Treatment of 16 Patients with Advanced Non-Small-Cell Lung Cancer

关键词:  非小细胞肺癌  吉非替尼  靶向治疗

Key words:  non-small-cell lung cancer  gefitinib  targeted therapy

摘要:

目的 观察吉非替尼单药治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法 对16例化疗失败的晚期NSCLC患者给予吉非替尼口服250 mg·d^-1，至病情进展或出现不可耐受的不良反应。结果 16例晚期NSCLC患者中，无完全缓解者，部分缓解(PR)4例(25.0%)，稳定(SD)6例(37.5%)，临床获益率(PR+SD)为62.5%。临床获益率与性别、吸烟史及癌症分期无关。到随访截止日期，16例患者中，6例存活，10例死亡；中位肿瘤进展时间(TTP)为7个月，中位生存期(MST)为10个月。不良反应主要为Ⅰ～Ⅱ度皮疹和腹泻，对症处理后可缓解。结论 吉非替尼有明显抗肿瘤作用，能明显提高晚期NSCLC患者的生活质量，改善临床症状，不良反应可以耐受。

Abstract:

OBJECTIVE To observe the effect of gefitinib monotherapy in the treatment of advanced non-small cell lung cancer(NSCLC) and the adverse reactions. METHODS For 16 cases of failure of chemotherapy in advanced NSCLC were treated with oral gefitinib 250 mg·d^-1, until the patients can not tolerate the side effects. RESULTS Among the 16 cases of advanced NSCLC patients, 4 cases(25.0%) had no complete remission or partial remission (PR), 6 cases (37.5%) keep stable(SD), clinical benefit rate (PR+SD) was 62.5%. There were no relationship between the clinical benefit rates and sex, smoking history or cancer staging. After follow-up, among 16 patients, 6 cases survived, 10 patients died. The TTP was 7 months, the MST was 10 months, respectively. The mainly adverse reactions were Ⅰ-Ⅱ degree of skin rash and diarrhea, and can be alleviated through symptomatic treatment. CONCLUSION Gefitinib has significant anti-tumor effects, can significantly improve the life quality of patients with advanced NSCLC, improve clinical symptoms, and the adverse reactions can be tolerated．